ghk cu scar Copper Peptide Serum GHK Cu Copper Peptide Serum

The injectable form was placed on the FDA's Category 2 bulk drug substances list in 2023, restricting compounding pharmacies from preparing it under Section 503A

at the cellular level this reprograms metabolic signaling (e.g., sirtuin-dependent pathways) and has been shown in vitro and in rodent studies to lower 1-MNA , reduce adipocyte lipogenesis/size , and increase energy expenditure

At-home microinfusion at 0.5mm is texture maintenance and post-procedure care between in-office sessions, not a primary scar treatment

Active malignancy requires careful evaluation Tissue-repair signaling activity may not be appropriate in patients with active or recent malignancy